Research Progress of Tumor Immunotherapy Target CD73 and Its Inhibitors
10.13748/j.cnki.issn1007-7693.20230605
- VernacularTitle:肿瘤免疫治疗靶点CD73及其抑制剂研究进展
- Author:
WANG Wenze
1
;
CHEN Yuepeng
1
;
CEN Lifang
1
;
ZOU Yi
2
;
XU Yungen
2
Author Information
1. Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China
2. Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, ChinaJiangsu Key Laboratory of Drug Molecular Design and Optimization, Nanjing 211198, China
- Publication Type:Journal Article
- Keywords:
CD73;
adenosine;
small molecule inhibitors;
cancer immunotherapy
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(13):1864-1878
- CountryChina
- Language:Chinese
-
Abstract:
Adenosine has been proved to have immunosuppressive effect in many different diseases, and the activity of ecto-5’-nucleotidase(CD73) on the cell surface is the rate-limiting step of extracellular adenosine production. CD73 has a profound and lasting impact on tumor immune regulation of regulatory T cells, B cells, macrophages and natural killer cells. CD73-mediated adenosine pathway is significant in signal transduction during cancer progression in tumor microenvironment, making CD73 a novel immune checkpoint. Therefore, CD73 inhibition is a emergent and promising strategy for cancer immunotherapy. At present, a variety of monoclonal antibodies and small molecule inhibitors have been in clinical development. This review comprehensively summarizes the frontier research progress of reported small molecule CD73 inhibitors, which can provide guidance for the investigation of novel CD73 inhibitors for cancer therapy.
